Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Union Inks China Deal For Promising Skin Drug Orismilast

A Potential Rival To Amgen's Otezla

Executive Summary

Innovent is paying the Danish biotech $20m upfront for the China rights to the mid-stage PDE4 inhibitor that is being developed for psoriasis, atopic dermatitis and hidradenitis suppurativa. 

You may also be interested in...



Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy

Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.

Evelo’s Phase II Data Suggest Strong Position In Mild-To-Moderate Psoriasis

Analysts say biotech’s EDP1815 may offer similar efficacy to Amgen’s Otezla, with better safety. Evelo says data offer new proof for its small intestinal axis approach to inflammatory disease.

AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA

After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel